CA2623018A1 - Pharmaceutical compositions of telmisartan - Google Patents
Pharmaceutical compositions of telmisartan Download PDFInfo
- Publication number
- CA2623018A1 CA2623018A1 CA002623018A CA2623018A CA2623018A1 CA 2623018 A1 CA2623018 A1 CA 2623018A1 CA 002623018 A CA002623018 A CA 002623018A CA 2623018 A CA2623018 A CA 2623018A CA 2623018 A1 CA2623018 A1 CA 2623018A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- telmisartan
- amount
- composition according
- diluent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 title claims abstract description 172
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 118
- 239000005537 C09CA07 - Telmisartan Substances 0.000 title claims abstract description 94
- 229960005187 telmisartan Drugs 0.000 title claims abstract description 90
- 239000003085 diluting agent Substances 0.000 claims abstract description 71
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 71
- 239000000203 mixture Substances 0.000 claims abstract description 68
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 26
- 239000004094 surface-active agent Substances 0.000 claims abstract description 24
- -1 telmisartan compound Chemical class 0.000 claims abstract description 21
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 20
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 20
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 20
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims description 42
- 239000008187 granular material Substances 0.000 claims description 32
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 25
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 23
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 23
- 239000000945 filler Substances 0.000 claims description 20
- 239000007884 disintegrant Substances 0.000 claims description 19
- 239000011230 binding agent Substances 0.000 claims description 16
- 238000005469 granulation Methods 0.000 claims description 16
- 230000003179 granulation Effects 0.000 claims description 16
- 239000000314 lubricant Substances 0.000 claims description 16
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 16
- 239000008109 sodium starch glycolate Substances 0.000 claims description 16
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 16
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 15
- 239000000600 sorbitol Substances 0.000 claims description 15
- 235000010356 sorbitol Nutrition 0.000 claims description 15
- 239000002552 dosage form Substances 0.000 claims description 14
- 229940069328 povidone Drugs 0.000 claims description 13
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims description 12
- 229960003194 meglumine Drugs 0.000 claims description 12
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical group CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 229920001993 poloxamer 188 Polymers 0.000 claims description 10
- 229940044519 poloxamer 188 Drugs 0.000 claims description 10
- 239000008240 homogeneous mixture Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 238000004513 sizing Methods 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 2
- 150000004679 hydroxides Chemical class 0.000 claims description 2
- 235000021317 phosphate Nutrition 0.000 claims description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229940068965 polysorbates Drugs 0.000 claims description 2
- 239000003826 tablet Substances 0.000 description 34
- 239000000546 pharmaceutical excipient Substances 0.000 description 16
- 238000009472 formulation Methods 0.000 description 14
- 239000002775 capsule Substances 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000007916 tablet composition Substances 0.000 description 6
- 229920003084 Avicel® PH-102 Polymers 0.000 description 5
- 238000007907 direct compression Methods 0.000 description 5
- 238000007922 dissolution test Methods 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229940101564 micardis Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 229940033134 talc Drugs 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000036515 potency Effects 0.000 description 3
- 229920003124 powdered cellulose Polymers 0.000 description 3
- 235000019814 powdered cellulose Nutrition 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000005555 hypertensive agent Substances 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 206010051113 Arterial restenosis Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 229920003072 Plasdone™ povidone Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000012615 aggregate Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 208000026533 urinary bladder disease Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940057977 zinc stearate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides a pharmaceutical composition of telmisartan comprising a) a telmisartan compound, b) a surfactant, c) a basic agent, and d) at least one diluent wherein the composition comprises less than 25% of water soluble diluents. The telmisartan compound is preferably present from about 12.5% to about 15.5%. At least one water insoluble diluent is preferred for use in the pharmaceutical composition in an amount from about 40% to about 70% of the total weight of the pharmaceutical composition. A preferred water insoluble diluent is microcrystalline cellulose.
Description
PHARMACEUTICAL COMPOSITIONS OF TELMISARTAN
FIELD OF THE INVENTION
The present invention is directed to pharmaceutical compositions of telmisartan having less than 25% of water soluble diluents.
BACKGROUND OF THE INVENTION
Telmisartan is the common chemical name for the compound 4'-[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid.
(CAS
Registry No.144701-48-4.) The empirical formula of telmisartan is C33H30N402 and its molecular weight is 514.63. The molecular structure of telmisartan is represented by Formula I.
~CH3 ~ ~ \ \
N
Formula I
Telmisartan is a non-peptide angiotensin II receptor (type ATl) antagonist.
The United States Food and Drug Administration (FDA) approved it for the treatment of hypertension. It may be used alone or in combination with other hypertensive agents, such as hydrochlorothiazide. Boehringer Ingelheim markets telmisartan under the trade name Micardis (telmisartan), available as 20, 40 and 80 mg tablets for oral administration.
Two patents are listed in the FDA's electronic Orange Book for telmisartan, U.S. Patent No.
6,358,986 ("the '986 patent") and U.S. Patent No. 5,591,762 ("the '762 patent").
The '986 patent apparently describes that telmisartan and the physiologically acceptable salts thereof can also be used to treat cardiac insufficiency, ischaemic peripheral circulatory disorders, myocardial ischaemia (angina), diabetic neuropathy, glaucoma, gastrointestinal diseases, bladder diseases, and to prevent progression of cardiac insufficiency after myocardial infarct.
In addition to the above therapeutic applications of telmisartan, the '762 patent discloses other therapeutic applications, including treating diabetic nephropathy, pulmonary diseases, e.g., lung oedema and chronic bronchitis. It also discloses using telmisartan to prevent arterial restenosis after angioplasty, thickening of blood vessel walls after vascular operations, and diabetic angiopathy. The '762 patent further discloses using telmisartan to alleviate central nervous system disorders, such as depression, Alzheimer's disease, Parkinson Syndrome, bulimia, and disorders of cognitive function in view of the effects of angiotensin on the release of acetylchloline and dopamine in the brain.
Telmisartan is a white to off-white, odorless crystalline powder. It is practically insoluble in water or an aqueous solution in the pH range of 3 to 9, and sparingly soluble in a strong acid, with the exception of hydrochloric acid in which it is insoluble. Telmisartan is soluble in a strong base.
In general, Telmisartan is manufactured and supplied in its free acid form.
However, as described in WO 00/43370, crystalline Telmisartan apparently exists in two polymorphic forms which have different melting points. Under the influence of heat and humidity polymorph B of Telmisartan, having the lower melting point, reportedly irreversibly transforms into polymorph A, which has a higher melting point. Both of these forms are apparently very poorly soluble in aqueous systems at the physiological pH range in the gastro-intestinal tract of between pH 1 to 7.
The published U.S. patent application 2004/0110813 Al, describes that the solubility of Telmisartan can be increased several hundred fold in a pharmaceutical composition comprising 3 to 50% of Telmisartan dispersed in a dissolving matrix comprising a) a basic agent wherein the molar ratio of basic agent: Telmisartan equals 1:1 to 10:1, b) a surfactant or emulsifier in an amount of about 2 to 3% of the final composition, c) 25 to 70% of a water soluble diluent, and optionally 0 to 20% of further excipients and/or adjuvants.
The present invention is directed to pharmaceutical compositions comprising telmisartan in which the solubility of telmisartan is improved, and wherein the composition comprises less than 25% of water soluble diluents.
SUMMARY OF THE INVENTION
The present invention provides a pharmaceutical composition comprising a) a telmisartan compound, b) a surfactant, c) a basic agent, and d) at least one diluent selected from water soluble and water insoluble diluents, wherein the pharmaceutical composition comprises less than 25% by total weight of the composition of water soluble diluents.
Preferably the pharmaceutical composition comprises at least one diluent which is water insoluble, preferably microcrystalline cellulose.
Unexpectedly, it was determined that telmisartan containing pharmaceutical compositions of the present invention provide sufficient solubility of telmisartan for use in a physiological environment while the amount of water soluble diluents is less than 25% of the composition by weight. Telmisartan is released from said pharmaceutical compositions with sufficient solubility for gastro-intestinal absorption in the slightly acidic and neutral pH region.
In one embodiment of the invention dissolution of the pharmaceutical composition in an aqueous solution of neutral pH dissolves at least 80% of the Telmisartan contained therein within 45 minutes. Preferably, at least 80% of the Telmisartan is dissolved from the pharmaceutical composition in such aqueous solution within 30 minutes, and most preferably at least 80% of the Telmisartan is dissolved from the pharmaceutical composition in such aqueous solution within 20 minutes.
In another embodiment of the present invention there is provided a pharmaceutical composition comprising about 12.5% to about 15.5% weight percent of telmisartan; about 40%
to about 70% weight percent microcrystalline cellulose; about 2.0% to about 3.5% weight percent of a surfactant, preferably Poloxamer 188; about 9% to about 12%
weight percent of a basic agent, preferably Meglumine; about 1.0% to about 1.5% weight percent of a binder; about 7.5% to about 10% weight of a disintegrant; about 0% to 17% weight percent of a water soluble filler and about 0.5% to about 1% weight of a lubricant, all weight percentages are based upon the total weight of the pharmaceutical composition.
Further there is provided a method of preparing a pharmaceutical composition comprising the following steps of 1) mixing a disintegrant, preferably sodium starch glycolate, and one or more diluents, preferably at least one water insoluble diluent, more preferably wherein at least one diluent is microcrystalline cellulose, in a high shear mixer to form a homogeneous mixture; 2) preparing a granulation suspension of purified water, alcohol, a basic agent, a surfactant, and telmisartan; 3) combining the homogeneous mixture and the granulation suspension to form a combined mixture; 4) preparing a granulation solution of water and a binder, preferably Povidone (preferably PVP K-30); 5) adding the granulation solution to the combined mixture to form a granulate; 6) drying the formed granules; 7) sizing the dried granules; 8) mixing the dried granulate with a disintegrant, preferably sodium starch glycolate, and optionally a filler, preferably sorbitol, and; 9) adding a lubricant, preferably magnesium stearate; and 10) compressing the granules into tablets, wherein the prepared pharmaceutical composition comprises less than 25% by weight of water soluble diluents.
Further, when the pharmaceutical composition to be prepared is a capsule as opposed to tablets, step 10 of the method is replaced by a step of filling capsules.
In another embodiment of the present invention there is provided a method of treating a patient suffering from hypertension comprising administering an effective amount of a telmisartan compound in a pharmaceutical composition comprising about 12.5% to about 15.5%
of a telmisartan compound; about 2.0 to about 3.5% of a surfactant; about 9%
to about 12% of a basic agent; and at least one diluent, wherein the pharmaceutical composition comprises less than 25% of water soluble diluents. Preferably, the pharmaceutical composition comprises about 40%
to about 70% of a water insoluble diluent.
DETAILED DESCRIPTION OF THE INVENTION
As used throughout this specification, the term water soluble diluent refers to a compound, used in the art as a diluent, for use in a pharmaceutical composition which is soluble in an aqueous environment. In contrast, the term water insoluble diluent refers to a compound, used in the art as a diluent, for use in a pharmaceutical composition which is insoluble or very poorly soluble in an aqueous environment.
The pharmaceutical composition according to the invention comprises:
a) a telmisartan compound, in admixture with b) a surfactant, c) a basic agent, and d) at least one diluent selected from water soluble and water insoluble diluents, wherein the amount of water soluble diluents in the pharmaceutical composition is less than 25% by weight of the pharmaceutical composition. Preferably, the amount of water soluble diluents in the pharmaceutical composition is less than 20%, more preferably less than 17.5%, by weight of the pharmaceutical composition. Said pharmaceutical composition preferably comprises at least one water insoluble diluent.
Preferably, a pharmaceutical composition of the invention is in tablet dosage form containing telmisartan as the active ingredient in an amount of 20, 40 or 80 mg in each tablet, and wherein the total weight of the pharmaceutical composition is from about 130mg to about 160mg. More preferably, such tablets contain 20 mg of telmisartan. The relative amount of the telmisartan compound typically varies from about 12.5% to about 15.5% by weight of the pharmaceutical composition. Further, telmisartan as used in the pharmaceutical composition of the present invention may be in any suitable form such as for example in the form of polymorph A or B.
Suitable diluents for use in the pharmaceutical composition of the invention include microcrystalline cellulose (e.g. Avicel ), microfine cellulose, lactose, starch, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, potassium chloride, powdered cellulose, sodium chloride, sorbitol and talc. However, the total amount of water soluble diluents in the pharmaceutical composition is less than 25% by weight of the pharmaceutical composition. In a preferred embodiment of the invention at least one diluent for use in the pharmaceutical composition is a water insoluble diluent such as microcrystalline cellulose. Preferably, the insoluble diluent for use in the pharmaceutical composition of the invention is microcrystalline cellulose (e.g. Avicel PH 102).
In such prefered embodiment of the invention, the relative amount of the water insoluble diluent is preferably from about 40% to about 70% by weight of the pharmaceutical composition.
Suitable surfactants for use in the pharmaceutical composition of the invention include poloxamers, polyethylene glycols, polysorbates, sodium lauryl sulfate, polyethoxylated castor oil, and hydroxylated castor oil. A preferred surfactant for use in the pharmaceutical composition of the invention is Poloxamer 188. Preferably, the pharmaceutical composition comprises an amount of about 2.0% to about 3.5% by total weight of the composition of the surfactant.
Suitable basic agents for use in the pharmaceutical composition of the invention include alkaline hydroxides, alkaline carbonates, alkaline phosphates, basic amino acids, and Meglumine. A preferred basic agent for use in the pharmaceutical composition of the invention is Meglumine. Preferably, the pharmaceutical composition comprises an amount of about 9% to about 12% by total weight of the composition of the basic agent.
The telmisartan pharmaceutical composition of the invention may also include pharmaceutically acceptable excipients. As is well known to those skilled in the art, pharmaceutical excipients are routinely incorporated into solid dosage forms.
This is done to ease the manufacturing process as well as to improve the performance of the dosage form.
Comriion excipients include fillers, binders, lubricants, etc. Such excipients could be used in the dosage forms of this invention.
Fillers, are added in order to increase the mass of an individual dose to a size suitable for tablet compression. Suitable fillers include for example powdered sugar, calcium phosphate, calcium sulfate, microcrystalline cellulose, lactose, mannitol, kaolin, sodium chloride, dry starch, sorbitol, and talc. A water soluble filler may optionally be used. A preferred filler of this type for use in the pharmaceutical composition of the invention is sorbitol in an amount not exceeding 25% by total weight of the composition. Preferably, the pharmaceutical composition comprises an amount of about 0% to about 17% by total weight of the composition of the optional filler.
Solid pharmaceutical compositions that are compacted into a dosage form, ' such as a tablet, may include excipients whose functions include helping to bind the active ingredient and other excipients together after compression. Binders for solid pharmaceutical compositions include acacia, alginic acid, carbomer (e.g. carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g.
Klucel ), hydroxypropyl methyl cellulose (e.g. Methocel'~'), liquid glucose, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. Povidone PVP K-30, Kollidon , Plasdone ), pregelatinized starch, sodium alginate and starch. A preferred binder for use in the pharinaceutical composition of the present invention is Povidone (e.g. PVP K-30). Preferably, the pharmaceutical composition comprises an amount of about 1.0% to about 1.5%
by total weight of the composition of the binder.
A compacted solid pharmaceutical composition may also include the addition of a disintegrant to the composition. Disintegrants include croscarmellose sodium (e.g. Ac Di Sol , Primellose ), crospovidone (e.g. Kollidori , Polyplasdone ), microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium starch glycolate (e.g.
Explotab , Primoljel ) and starch. A preferred disintegrant for use in the pharmaceutical composition of the invention is sodium starch glycolate. Preferably, the pharmaceutical composition comprises an amount of about 7.5% to about 10% by total weight of the composition of the disintegrant.
Glidants can be added to improve the flowability of a non compacted solid composition and to improve the accuracy of dosing. Excipients that may function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, and talc.
A lubricant can be added to the composition to reduce adhesion and/or ease the release of the product from e.g. the dye. Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate. A preferred lubricant for use in the pharmaceutical composition of the invention is magnesium stearate. Preferably, the pharmaceutical composition comprises an amount of about 0.5% to about 1.0% by total weight of the composition of the lubricant.
Other excipients that may be incorporated into the formulation include preservatives, antioxidants, or any other excipient commonly used in the pharmaceutical industry.
The solid compositions of the present invention include powders, granulates, aggregates and compacted compositions. The dosages include dosages suitable for oral, buccal, and rectal administration. Although the most suitable administration in any given case will depend on the nature and severity of the condition being treated, the most preferred route of the present invention is oral. The dosages may be conveniently presented in unit dosage form and prepared by any of the methods well known in the pharmaceutical arts.
Dosage forms include solid dosage forms like tablets, powders, capsules, sachets, troches and losenges.
The dosage form of the present invention may be a capsule containing the composition, preferably a powdered or granulated solid composition of the invention, within either a hard or soft shell. The shell may be made from gelatin and optionally contain a plasticizer such as glycerin and sorbitol, and an opacifying agent or colorant.
Particularly preferred pharmaceutical compositions of the invention are described in Table 1 infra, wherein all weight percentages are based upon the total weight of the composition.
Table 1: Preferred Pharmaceutical Compositions of the Invention Telmisartan Active Drug 12.5-15.5 Microcrystalline Cellulose (Avicel PH 102) Water Insoluble Diluent 40-70 Poloxamer 188 Surfactant 2.0-3.5 Meglumine Basic Agent 9-12 Povidone (PVP K-30) Binder 1.0-1.5 Sodium starch glycolate Disintegrant 7.5-10 Sorbitol Filler 0-17 Magnesium Stearate Lubricant 0.5-1.0 The solubility of telmisartan is sufficient for gastro-intestinal absorption from such pharmaceutical compositions of telmisartan in the slightly acidic and neutral pH region.
Telmisartan dissolves from the pharmaceutical composition of the present invention at a suitable rate. Preferably, at least 80% of the telmisartan in the pharmaceutical composition dissolves in a neutral aqueous environment within 45 minutes. More preferably, at least 80%
of the telmisartan in the pharmaceutical composition dissolves in a neutral aqueous environment within 30 minutes, and most preferably at least 80% of the Telmisartan is dissolved from the pharmaceutical composition in such aqueous solution within 20 minutes.
The active ingredient and excipients may be formulated into compositions and dosage forms according to methods known in the art.
A composition for tableting or capsule filling may be prepared by wet granulation. In wet granulation, some or all of the active ingredients and excipients in powder form are blended and then further mixed in the presence of a liquid, typically water, that causes the powders to clump into granules. The granulate is screened and/or milled, dried and then screened and/or milled to the desired particle size. The granulate may then be tableted, or other excipients may be added prior to tableting, such as a glidant and/or a lubricant.
A tableting composition may be prepared conventionally by dry blending. For example, the blended composition of the actives and excipients may be compacted into a slug or a sheet and then comminuted into compacted granules. The compacted granules may subsequently be compressed into a tablet. The granulates and powder blends produced by these methods can alternatively be filled into capsules or sachets for example.
As an alternative to dry granulation, a blended conlposition may be compressed directly into a compacted dosage form using direct compression techniques. Direct compression produces a more uniform tablet without granules. Excipients that are particularly well suited for direct compression tableting include microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate and colloidal silica. The proper use of these and other excipients in direct compression tableting is known to those in the art with experience and skill in particular fomiulation challenges of direct compression tableting.
A capsule filling of the present invention may comprise any of the aforementioned blends and granulates that were described with reference to tableting, however, they are not subjected to a final tableting step.
A preferred method of preparing a telmisartan pharmaceutical composition of the invention comprises the steps of 1) mixing a disintegrant, preferably sodium starch glycolate, and one or more diluents, preferably at least one water insoluble diluent, more preferably wherein at least one diluent is microcrystalline cellulose, in a high shear mixer to form a homogeneous mixture; 2) preparing a granulation suspension of purified water, alcohol, a basic agent, a surfactant, and telmisartan; 3) combining the homogeneous mixture and the granulation suspension to form a combined mixture; 4) preparing a granulation solution of water and a binder, preferably Povidone (e.g. PVP K-30); 5) adding the granulation solution to the combined mixture to form a granulate; 6) drying the formed granules; 7) sizing the dried granules; 8) mixing the dried granulate with a filler, preferably sorbitol, and a disintegrant, preferably sodium starch glycolate; 9) adding a lubricant, preferably magnesium stearate to form a final mixture;
and 10) compressing the final mixture into tablets, wherein the prepared pharmaceutical composition comprises less than 25% by weight of water soluble diluents. In preparing capsules step 10 will typically be replaced by the step of filling capsule shells. The method of the present invention is however not limited to these mixing procedures or their order, and several of the steps involved can be combined into a single step.
In the above method the amount of disintegrant used preferably results in a pharmaceutical composition comprising about 7.5% to about 10% of a disintegrant. Also, the amount of a telmisartan compound used in said method preferably results in a pharmaceutical composition comprising about 12.5% to about 15.5% of a telmisartan compound.
The amount of a basic agent used in said method preferably results in a pharmaceutical composition comprising about 9% to about 12% of a basic agent. The amount of a binder used in said method preferably results in a pharmaceutical composition comprising about 1.0% to about 1.5% of a binder.
Further, the amount of surfactant used in said method preferably results in a pharmaceutical composition comprising about 2.0% to about 3.5% of a surfactant. The amount of an optional filler used in said method preferably results in a pharmaceutical composition comprising about 0% to about 17% of a filler. The amount of a lubricant used in said method is preferably from about 0.5% to about 1.0%.
Telmisartan is used for the treatment of hypertension in patients, either alone or in combination with other hypertensive agents. The pharmaceutical compositions of the present invention provide an effective delivery system for the administration of telmisartan to patients in need of such treatment. Treatment of hypertensive patients may comprise administering an effective amount of telmisartan in a pharmaceutical composition comprising about 12.5% to about 15% telmisartan, about 2.0 to about 3.5% of a surfactant; about 9% to about 12% of a basic agent; and at least one diluent, wherein the pharmaceutical composition comprises less than 25% of water soluble diluents. Preferably, the pharmaceutical composition comprises about 40%
to about 70% of a water insoluble diluent.
The following examples are presented in order to further illustrate the invention. These examples should not be construed in any manner to limit the invention.
EXAMPLES
Example 1: Telmisartan formulations comprising 41% of a water insoluble diluent.
Telmisartan tablets were prepared containing 41% of a water insoluble diluent.
Sorbitol, a filler in these formulations, may also be considered a water soluble diluent and is thus present in less than 25%, i.e. 16.7%, of the composition. The tablets were prepared in three potencies, 20, 40 and 80 mg Telmisartan tablets. The tablet compositions are presented in Table 2.
Table 2: Telmisartan formulations comprising 41 % of a water insoluble diluent.
s I
i 1 Telmisartan 20 40 80 15.4 Microcrystalline Cellulose (Avicel PH 102) 54 108 216 41.5 Poloxamer 188 4 8 16 3.1 Meglumine 15 30 60 11.5 Povidone (PVP K-30) 2 4 8 1.5 Sodium starch glycolate 12 24 48 9.2 Sorbitol 21.75 43.5 87 16.7 Magnesium Stearate 1.25 2.5 5 1.0 Total 130.0 260.0 520.0 100.0 The tablets were prepared by mixing a homogeneous mixture of microcrystalline cellulose and sodium starch glycolate with a granulation suspension of purified water, Poloxamer 188, Meglumine, and telmisartan in a high shear mixer to form a partial granulate mixture. This partial granulate mixture was granulated with a granulation solution of alcohol and Povidone (PVP K-30). The obtained granules were dried in a Fluid Bed dryer until the observed "loss on drying" (LOD) was 2% or less. The dried granules were then milled by passing them through an oscillating granulator. Subsequently, the milled granulates were mixed with Sorbitol and sodium starch glycolate in a blender. The obtained blend was then mixed with magnesium stearate and tablets were prepared by compressing this mixture.
Example 2: Telmisartan formulations comprising 53% of a water insoluble diluent.
Telmisartan tablets were prepared containing 53% of a water insoluble diluent.
Sorbitol, a filler in these formulations, may also be considered a water soluble diluent and is thus present in an amount less than 25%, i.e. 13.4%, of the composition. The tablets were prepared in three potencies, 20, 40 and 80 mg Telmisartan tablets. The tablet compositions are presented in Table 3.
Table 3: Telmisartan formulations comprising 53% of a water insoluble diluent.
7106Telmisartan 20 80 12.5 Microcrystalline Cellulose (Avicel PH 102) 84 336 52.5 Poloxamer 188 4 16 2.5 Meglumine 15 30 60 9.375 Povidone (PVP K-30) 2 4 8 1.25 Sodium starch glycolate 12 24 48 7.5 Sorbitol 21.4 42.8 85.6 13.375 Magnesium Stearate 1.6 3.2 6.4 1.0 Total 160.0 320.0 640.0 100.0 The tablets were prepared by wet granulation by mixing a homogeneous mixture of microcrystalline cellulose and sodium starch glycolate with a granulation suspension of purified water, Poloxamer 188, Meglumine, and telmisartan in a high shear mixer to form a partial granulate mixture. This partial granulate mixture was granulated with a granulation solution of alcohol and Povidone (PVP K-30). The obtained granules were dried in a Fluid Bed dryer until the observed "loss on drying" (LOD) was 2% or less. The dried granules were then milled by passing them through an oscillating granulator. Subsequently, the milled granulates were mixed with Sorbitol and sodium starch glycolate in a blender. The obtained blend was then mixed with magnesium stearate and tablets were prepared by compressing this mixture.
Example 3: Telmisartan formulations comprising 66% of a water insoluble diluent.
Telmisartan tablets were prepared containing 66% of a water insoluble diluent.
Moreover, these formulations do not comprise water soluble diluents. The tablets were prepared in three potencies, 20, 40 and 80 mg Telmisartan tablets. The tablet compositions are presented in Table 4.
Table 4: Telmisartan formulations comprising 66% of a water insoluble diluent.
1~..~ i .#I E..t1rs . .~ ~ .. r t ~ 1 4 ~ { S ;~v~~ .3 ~ !~'. E{ik= '~ S ~~~
ki ~s ~.;i~ 1 w:~ ~ii: ~
Telmisartan 20 40 80 12.5 Microcrystalline Cellulose (Avicel PH 102) 105.4 210.8 421.6 65.875 Poloxamer 188 4 8 16 2.5 Meglumine 15 30 60 9.375 Povidone (PVP K-30) 2 4 8 1.25 Sodium starch glycolate 12 24 48 7.5 Magnesium Stearate 1.6 3.2 6.4 1.0 Total 160.0 320.0 640.0 100.0 The tablets were prepared by wet granulation through a method analogous to the method used to prepare the tablets of example 1.
Example 4: Dissolution tests with Telmisartan pharmaceutical tablet dosage forms.
Dissolution tests with the Telmisartan pharmaceutical tablet dosage formulations of examples 1 to 3 were performed. In these tests the dissolution of the tablets of examples 1 to 3 was compared with the dissolution of the reference tablet formulation, a Micardis tablet. These in vitro dissolution tests were conducted using an Apparatus II (Paddle Method) as described in the United State Pharmacopeia XXI/National Formulary XVI. The comparative dissolution tests were conducted under the following conditions. Micardis tablets and Telmisartan tablets of examples 1, 2, and 3 were dissolved in a USP type II apparatus at a paddle speed of 75 rpm, at a temperature of 37 C, in 900ml of a buffer at pH 7.5. The results of these dissolution tests are presented in Table 5.
Table 5: Comparative dissolution.
.
F " i a F k F ~ ~
F~~fJ, 51~~If ~h-kt ] ~ r'~~ =~~f#s~{~~j}{ i~+r~~lf~ Ji ~ } 1 ~ 3~ .. e Based upon these dissolution studies, the results appearing in Table 5 above, it can be concluded that the pharmaceutical tablet formulations of the present invention and the reference Micardis tablet all dissolve at least 80% of the telmisartan contained therein well within the desired 45 minutes. In fact, all dissolve at least 80% of the telmisartan contained in the formulation within 30 minutes, and some formulations even achieve that at least 80% of the telmisartan from the pharmaceutical composition is dissolved in such aqueous solution within 20 minutes. The results further demonstrate that the pharmaceutical tablet formulations of the invention have a similar dissolution profile compared to the 'reference formulation.
FIELD OF THE INVENTION
The present invention is directed to pharmaceutical compositions of telmisartan having less than 25% of water soluble diluents.
BACKGROUND OF THE INVENTION
Telmisartan is the common chemical name for the compound 4'-[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid.
(CAS
Registry No.144701-48-4.) The empirical formula of telmisartan is C33H30N402 and its molecular weight is 514.63. The molecular structure of telmisartan is represented by Formula I.
~CH3 ~ ~ \ \
N
Formula I
Telmisartan is a non-peptide angiotensin II receptor (type ATl) antagonist.
The United States Food and Drug Administration (FDA) approved it for the treatment of hypertension. It may be used alone or in combination with other hypertensive agents, such as hydrochlorothiazide. Boehringer Ingelheim markets telmisartan under the trade name Micardis (telmisartan), available as 20, 40 and 80 mg tablets for oral administration.
Two patents are listed in the FDA's electronic Orange Book for telmisartan, U.S. Patent No.
6,358,986 ("the '986 patent") and U.S. Patent No. 5,591,762 ("the '762 patent").
The '986 patent apparently describes that telmisartan and the physiologically acceptable salts thereof can also be used to treat cardiac insufficiency, ischaemic peripheral circulatory disorders, myocardial ischaemia (angina), diabetic neuropathy, glaucoma, gastrointestinal diseases, bladder diseases, and to prevent progression of cardiac insufficiency after myocardial infarct.
In addition to the above therapeutic applications of telmisartan, the '762 patent discloses other therapeutic applications, including treating diabetic nephropathy, pulmonary diseases, e.g., lung oedema and chronic bronchitis. It also discloses using telmisartan to prevent arterial restenosis after angioplasty, thickening of blood vessel walls after vascular operations, and diabetic angiopathy. The '762 patent further discloses using telmisartan to alleviate central nervous system disorders, such as depression, Alzheimer's disease, Parkinson Syndrome, bulimia, and disorders of cognitive function in view of the effects of angiotensin on the release of acetylchloline and dopamine in the brain.
Telmisartan is a white to off-white, odorless crystalline powder. It is practically insoluble in water or an aqueous solution in the pH range of 3 to 9, and sparingly soluble in a strong acid, with the exception of hydrochloric acid in which it is insoluble. Telmisartan is soluble in a strong base.
In general, Telmisartan is manufactured and supplied in its free acid form.
However, as described in WO 00/43370, crystalline Telmisartan apparently exists in two polymorphic forms which have different melting points. Under the influence of heat and humidity polymorph B of Telmisartan, having the lower melting point, reportedly irreversibly transforms into polymorph A, which has a higher melting point. Both of these forms are apparently very poorly soluble in aqueous systems at the physiological pH range in the gastro-intestinal tract of between pH 1 to 7.
The published U.S. patent application 2004/0110813 Al, describes that the solubility of Telmisartan can be increased several hundred fold in a pharmaceutical composition comprising 3 to 50% of Telmisartan dispersed in a dissolving matrix comprising a) a basic agent wherein the molar ratio of basic agent: Telmisartan equals 1:1 to 10:1, b) a surfactant or emulsifier in an amount of about 2 to 3% of the final composition, c) 25 to 70% of a water soluble diluent, and optionally 0 to 20% of further excipients and/or adjuvants.
The present invention is directed to pharmaceutical compositions comprising telmisartan in which the solubility of telmisartan is improved, and wherein the composition comprises less than 25% of water soluble diluents.
SUMMARY OF THE INVENTION
The present invention provides a pharmaceutical composition comprising a) a telmisartan compound, b) a surfactant, c) a basic agent, and d) at least one diluent selected from water soluble and water insoluble diluents, wherein the pharmaceutical composition comprises less than 25% by total weight of the composition of water soluble diluents.
Preferably the pharmaceutical composition comprises at least one diluent which is water insoluble, preferably microcrystalline cellulose.
Unexpectedly, it was determined that telmisartan containing pharmaceutical compositions of the present invention provide sufficient solubility of telmisartan for use in a physiological environment while the amount of water soluble diluents is less than 25% of the composition by weight. Telmisartan is released from said pharmaceutical compositions with sufficient solubility for gastro-intestinal absorption in the slightly acidic and neutral pH region.
In one embodiment of the invention dissolution of the pharmaceutical composition in an aqueous solution of neutral pH dissolves at least 80% of the Telmisartan contained therein within 45 minutes. Preferably, at least 80% of the Telmisartan is dissolved from the pharmaceutical composition in such aqueous solution within 30 minutes, and most preferably at least 80% of the Telmisartan is dissolved from the pharmaceutical composition in such aqueous solution within 20 minutes.
In another embodiment of the present invention there is provided a pharmaceutical composition comprising about 12.5% to about 15.5% weight percent of telmisartan; about 40%
to about 70% weight percent microcrystalline cellulose; about 2.0% to about 3.5% weight percent of a surfactant, preferably Poloxamer 188; about 9% to about 12%
weight percent of a basic agent, preferably Meglumine; about 1.0% to about 1.5% weight percent of a binder; about 7.5% to about 10% weight of a disintegrant; about 0% to 17% weight percent of a water soluble filler and about 0.5% to about 1% weight of a lubricant, all weight percentages are based upon the total weight of the pharmaceutical composition.
Further there is provided a method of preparing a pharmaceutical composition comprising the following steps of 1) mixing a disintegrant, preferably sodium starch glycolate, and one or more diluents, preferably at least one water insoluble diluent, more preferably wherein at least one diluent is microcrystalline cellulose, in a high shear mixer to form a homogeneous mixture; 2) preparing a granulation suspension of purified water, alcohol, a basic agent, a surfactant, and telmisartan; 3) combining the homogeneous mixture and the granulation suspension to form a combined mixture; 4) preparing a granulation solution of water and a binder, preferably Povidone (preferably PVP K-30); 5) adding the granulation solution to the combined mixture to form a granulate; 6) drying the formed granules; 7) sizing the dried granules; 8) mixing the dried granulate with a disintegrant, preferably sodium starch glycolate, and optionally a filler, preferably sorbitol, and; 9) adding a lubricant, preferably magnesium stearate; and 10) compressing the granules into tablets, wherein the prepared pharmaceutical composition comprises less than 25% by weight of water soluble diluents.
Further, when the pharmaceutical composition to be prepared is a capsule as opposed to tablets, step 10 of the method is replaced by a step of filling capsules.
In another embodiment of the present invention there is provided a method of treating a patient suffering from hypertension comprising administering an effective amount of a telmisartan compound in a pharmaceutical composition comprising about 12.5% to about 15.5%
of a telmisartan compound; about 2.0 to about 3.5% of a surfactant; about 9%
to about 12% of a basic agent; and at least one diluent, wherein the pharmaceutical composition comprises less than 25% of water soluble diluents. Preferably, the pharmaceutical composition comprises about 40%
to about 70% of a water insoluble diluent.
DETAILED DESCRIPTION OF THE INVENTION
As used throughout this specification, the term water soluble diluent refers to a compound, used in the art as a diluent, for use in a pharmaceutical composition which is soluble in an aqueous environment. In contrast, the term water insoluble diluent refers to a compound, used in the art as a diluent, for use in a pharmaceutical composition which is insoluble or very poorly soluble in an aqueous environment.
The pharmaceutical composition according to the invention comprises:
a) a telmisartan compound, in admixture with b) a surfactant, c) a basic agent, and d) at least one diluent selected from water soluble and water insoluble diluents, wherein the amount of water soluble diluents in the pharmaceutical composition is less than 25% by weight of the pharmaceutical composition. Preferably, the amount of water soluble diluents in the pharmaceutical composition is less than 20%, more preferably less than 17.5%, by weight of the pharmaceutical composition. Said pharmaceutical composition preferably comprises at least one water insoluble diluent.
Preferably, a pharmaceutical composition of the invention is in tablet dosage form containing telmisartan as the active ingredient in an amount of 20, 40 or 80 mg in each tablet, and wherein the total weight of the pharmaceutical composition is from about 130mg to about 160mg. More preferably, such tablets contain 20 mg of telmisartan. The relative amount of the telmisartan compound typically varies from about 12.5% to about 15.5% by weight of the pharmaceutical composition. Further, telmisartan as used in the pharmaceutical composition of the present invention may be in any suitable form such as for example in the form of polymorph A or B.
Suitable diluents for use in the pharmaceutical composition of the invention include microcrystalline cellulose (e.g. Avicel ), microfine cellulose, lactose, starch, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, potassium chloride, powdered cellulose, sodium chloride, sorbitol and talc. However, the total amount of water soluble diluents in the pharmaceutical composition is less than 25% by weight of the pharmaceutical composition. In a preferred embodiment of the invention at least one diluent for use in the pharmaceutical composition is a water insoluble diluent such as microcrystalline cellulose. Preferably, the insoluble diluent for use in the pharmaceutical composition of the invention is microcrystalline cellulose (e.g. Avicel PH 102).
In such prefered embodiment of the invention, the relative amount of the water insoluble diluent is preferably from about 40% to about 70% by weight of the pharmaceutical composition.
Suitable surfactants for use in the pharmaceutical composition of the invention include poloxamers, polyethylene glycols, polysorbates, sodium lauryl sulfate, polyethoxylated castor oil, and hydroxylated castor oil. A preferred surfactant for use in the pharmaceutical composition of the invention is Poloxamer 188. Preferably, the pharmaceutical composition comprises an amount of about 2.0% to about 3.5% by total weight of the composition of the surfactant.
Suitable basic agents for use in the pharmaceutical composition of the invention include alkaline hydroxides, alkaline carbonates, alkaline phosphates, basic amino acids, and Meglumine. A preferred basic agent for use in the pharmaceutical composition of the invention is Meglumine. Preferably, the pharmaceutical composition comprises an amount of about 9% to about 12% by total weight of the composition of the basic agent.
The telmisartan pharmaceutical composition of the invention may also include pharmaceutically acceptable excipients. As is well known to those skilled in the art, pharmaceutical excipients are routinely incorporated into solid dosage forms.
This is done to ease the manufacturing process as well as to improve the performance of the dosage form.
Comriion excipients include fillers, binders, lubricants, etc. Such excipients could be used in the dosage forms of this invention.
Fillers, are added in order to increase the mass of an individual dose to a size suitable for tablet compression. Suitable fillers include for example powdered sugar, calcium phosphate, calcium sulfate, microcrystalline cellulose, lactose, mannitol, kaolin, sodium chloride, dry starch, sorbitol, and talc. A water soluble filler may optionally be used. A preferred filler of this type for use in the pharmaceutical composition of the invention is sorbitol in an amount not exceeding 25% by total weight of the composition. Preferably, the pharmaceutical composition comprises an amount of about 0% to about 17% by total weight of the composition of the optional filler.
Solid pharmaceutical compositions that are compacted into a dosage form, ' such as a tablet, may include excipients whose functions include helping to bind the active ingredient and other excipients together after compression. Binders for solid pharmaceutical compositions include acacia, alginic acid, carbomer (e.g. carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g.
Klucel ), hydroxypropyl methyl cellulose (e.g. Methocel'~'), liquid glucose, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. Povidone PVP K-30, Kollidon , Plasdone ), pregelatinized starch, sodium alginate and starch. A preferred binder for use in the pharinaceutical composition of the present invention is Povidone (e.g. PVP K-30). Preferably, the pharmaceutical composition comprises an amount of about 1.0% to about 1.5%
by total weight of the composition of the binder.
A compacted solid pharmaceutical composition may also include the addition of a disintegrant to the composition. Disintegrants include croscarmellose sodium (e.g. Ac Di Sol , Primellose ), crospovidone (e.g. Kollidori , Polyplasdone ), microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium starch glycolate (e.g.
Explotab , Primoljel ) and starch. A preferred disintegrant for use in the pharmaceutical composition of the invention is sodium starch glycolate. Preferably, the pharmaceutical composition comprises an amount of about 7.5% to about 10% by total weight of the composition of the disintegrant.
Glidants can be added to improve the flowability of a non compacted solid composition and to improve the accuracy of dosing. Excipients that may function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, and talc.
A lubricant can be added to the composition to reduce adhesion and/or ease the release of the product from e.g. the dye. Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate. A preferred lubricant for use in the pharmaceutical composition of the invention is magnesium stearate. Preferably, the pharmaceutical composition comprises an amount of about 0.5% to about 1.0% by total weight of the composition of the lubricant.
Other excipients that may be incorporated into the formulation include preservatives, antioxidants, or any other excipient commonly used in the pharmaceutical industry.
The solid compositions of the present invention include powders, granulates, aggregates and compacted compositions. The dosages include dosages suitable for oral, buccal, and rectal administration. Although the most suitable administration in any given case will depend on the nature and severity of the condition being treated, the most preferred route of the present invention is oral. The dosages may be conveniently presented in unit dosage form and prepared by any of the methods well known in the pharmaceutical arts.
Dosage forms include solid dosage forms like tablets, powders, capsules, sachets, troches and losenges.
The dosage form of the present invention may be a capsule containing the composition, preferably a powdered or granulated solid composition of the invention, within either a hard or soft shell. The shell may be made from gelatin and optionally contain a plasticizer such as glycerin and sorbitol, and an opacifying agent or colorant.
Particularly preferred pharmaceutical compositions of the invention are described in Table 1 infra, wherein all weight percentages are based upon the total weight of the composition.
Table 1: Preferred Pharmaceutical Compositions of the Invention Telmisartan Active Drug 12.5-15.5 Microcrystalline Cellulose (Avicel PH 102) Water Insoluble Diluent 40-70 Poloxamer 188 Surfactant 2.0-3.5 Meglumine Basic Agent 9-12 Povidone (PVP K-30) Binder 1.0-1.5 Sodium starch glycolate Disintegrant 7.5-10 Sorbitol Filler 0-17 Magnesium Stearate Lubricant 0.5-1.0 The solubility of telmisartan is sufficient for gastro-intestinal absorption from such pharmaceutical compositions of telmisartan in the slightly acidic and neutral pH region.
Telmisartan dissolves from the pharmaceutical composition of the present invention at a suitable rate. Preferably, at least 80% of the telmisartan in the pharmaceutical composition dissolves in a neutral aqueous environment within 45 minutes. More preferably, at least 80%
of the telmisartan in the pharmaceutical composition dissolves in a neutral aqueous environment within 30 minutes, and most preferably at least 80% of the Telmisartan is dissolved from the pharmaceutical composition in such aqueous solution within 20 minutes.
The active ingredient and excipients may be formulated into compositions and dosage forms according to methods known in the art.
A composition for tableting or capsule filling may be prepared by wet granulation. In wet granulation, some or all of the active ingredients and excipients in powder form are blended and then further mixed in the presence of a liquid, typically water, that causes the powders to clump into granules. The granulate is screened and/or milled, dried and then screened and/or milled to the desired particle size. The granulate may then be tableted, or other excipients may be added prior to tableting, such as a glidant and/or a lubricant.
A tableting composition may be prepared conventionally by dry blending. For example, the blended composition of the actives and excipients may be compacted into a slug or a sheet and then comminuted into compacted granules. The compacted granules may subsequently be compressed into a tablet. The granulates and powder blends produced by these methods can alternatively be filled into capsules or sachets for example.
As an alternative to dry granulation, a blended conlposition may be compressed directly into a compacted dosage form using direct compression techniques. Direct compression produces a more uniform tablet without granules. Excipients that are particularly well suited for direct compression tableting include microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate and colloidal silica. The proper use of these and other excipients in direct compression tableting is known to those in the art with experience and skill in particular fomiulation challenges of direct compression tableting.
A capsule filling of the present invention may comprise any of the aforementioned blends and granulates that were described with reference to tableting, however, they are not subjected to a final tableting step.
A preferred method of preparing a telmisartan pharmaceutical composition of the invention comprises the steps of 1) mixing a disintegrant, preferably sodium starch glycolate, and one or more diluents, preferably at least one water insoluble diluent, more preferably wherein at least one diluent is microcrystalline cellulose, in a high shear mixer to form a homogeneous mixture; 2) preparing a granulation suspension of purified water, alcohol, a basic agent, a surfactant, and telmisartan; 3) combining the homogeneous mixture and the granulation suspension to form a combined mixture; 4) preparing a granulation solution of water and a binder, preferably Povidone (e.g. PVP K-30); 5) adding the granulation solution to the combined mixture to form a granulate; 6) drying the formed granules; 7) sizing the dried granules; 8) mixing the dried granulate with a filler, preferably sorbitol, and a disintegrant, preferably sodium starch glycolate; 9) adding a lubricant, preferably magnesium stearate to form a final mixture;
and 10) compressing the final mixture into tablets, wherein the prepared pharmaceutical composition comprises less than 25% by weight of water soluble diluents. In preparing capsules step 10 will typically be replaced by the step of filling capsule shells. The method of the present invention is however not limited to these mixing procedures or their order, and several of the steps involved can be combined into a single step.
In the above method the amount of disintegrant used preferably results in a pharmaceutical composition comprising about 7.5% to about 10% of a disintegrant. Also, the amount of a telmisartan compound used in said method preferably results in a pharmaceutical composition comprising about 12.5% to about 15.5% of a telmisartan compound.
The amount of a basic agent used in said method preferably results in a pharmaceutical composition comprising about 9% to about 12% of a basic agent. The amount of a binder used in said method preferably results in a pharmaceutical composition comprising about 1.0% to about 1.5% of a binder.
Further, the amount of surfactant used in said method preferably results in a pharmaceutical composition comprising about 2.0% to about 3.5% of a surfactant. The amount of an optional filler used in said method preferably results in a pharmaceutical composition comprising about 0% to about 17% of a filler. The amount of a lubricant used in said method is preferably from about 0.5% to about 1.0%.
Telmisartan is used for the treatment of hypertension in patients, either alone or in combination with other hypertensive agents. The pharmaceutical compositions of the present invention provide an effective delivery system for the administration of telmisartan to patients in need of such treatment. Treatment of hypertensive patients may comprise administering an effective amount of telmisartan in a pharmaceutical composition comprising about 12.5% to about 15% telmisartan, about 2.0 to about 3.5% of a surfactant; about 9% to about 12% of a basic agent; and at least one diluent, wherein the pharmaceutical composition comprises less than 25% of water soluble diluents. Preferably, the pharmaceutical composition comprises about 40%
to about 70% of a water insoluble diluent.
The following examples are presented in order to further illustrate the invention. These examples should not be construed in any manner to limit the invention.
EXAMPLES
Example 1: Telmisartan formulations comprising 41% of a water insoluble diluent.
Telmisartan tablets were prepared containing 41% of a water insoluble diluent.
Sorbitol, a filler in these formulations, may also be considered a water soluble diluent and is thus present in less than 25%, i.e. 16.7%, of the composition. The tablets were prepared in three potencies, 20, 40 and 80 mg Telmisartan tablets. The tablet compositions are presented in Table 2.
Table 2: Telmisartan formulations comprising 41 % of a water insoluble diluent.
s I
i 1 Telmisartan 20 40 80 15.4 Microcrystalline Cellulose (Avicel PH 102) 54 108 216 41.5 Poloxamer 188 4 8 16 3.1 Meglumine 15 30 60 11.5 Povidone (PVP K-30) 2 4 8 1.5 Sodium starch glycolate 12 24 48 9.2 Sorbitol 21.75 43.5 87 16.7 Magnesium Stearate 1.25 2.5 5 1.0 Total 130.0 260.0 520.0 100.0 The tablets were prepared by mixing a homogeneous mixture of microcrystalline cellulose and sodium starch glycolate with a granulation suspension of purified water, Poloxamer 188, Meglumine, and telmisartan in a high shear mixer to form a partial granulate mixture. This partial granulate mixture was granulated with a granulation solution of alcohol and Povidone (PVP K-30). The obtained granules were dried in a Fluid Bed dryer until the observed "loss on drying" (LOD) was 2% or less. The dried granules were then milled by passing them through an oscillating granulator. Subsequently, the milled granulates were mixed with Sorbitol and sodium starch glycolate in a blender. The obtained blend was then mixed with magnesium stearate and tablets were prepared by compressing this mixture.
Example 2: Telmisartan formulations comprising 53% of a water insoluble diluent.
Telmisartan tablets were prepared containing 53% of a water insoluble diluent.
Sorbitol, a filler in these formulations, may also be considered a water soluble diluent and is thus present in an amount less than 25%, i.e. 13.4%, of the composition. The tablets were prepared in three potencies, 20, 40 and 80 mg Telmisartan tablets. The tablet compositions are presented in Table 3.
Table 3: Telmisartan formulations comprising 53% of a water insoluble diluent.
7106Telmisartan 20 80 12.5 Microcrystalline Cellulose (Avicel PH 102) 84 336 52.5 Poloxamer 188 4 16 2.5 Meglumine 15 30 60 9.375 Povidone (PVP K-30) 2 4 8 1.25 Sodium starch glycolate 12 24 48 7.5 Sorbitol 21.4 42.8 85.6 13.375 Magnesium Stearate 1.6 3.2 6.4 1.0 Total 160.0 320.0 640.0 100.0 The tablets were prepared by wet granulation by mixing a homogeneous mixture of microcrystalline cellulose and sodium starch glycolate with a granulation suspension of purified water, Poloxamer 188, Meglumine, and telmisartan in a high shear mixer to form a partial granulate mixture. This partial granulate mixture was granulated with a granulation solution of alcohol and Povidone (PVP K-30). The obtained granules were dried in a Fluid Bed dryer until the observed "loss on drying" (LOD) was 2% or less. The dried granules were then milled by passing them through an oscillating granulator. Subsequently, the milled granulates were mixed with Sorbitol and sodium starch glycolate in a blender. The obtained blend was then mixed with magnesium stearate and tablets were prepared by compressing this mixture.
Example 3: Telmisartan formulations comprising 66% of a water insoluble diluent.
Telmisartan tablets were prepared containing 66% of a water insoluble diluent.
Moreover, these formulations do not comprise water soluble diluents. The tablets were prepared in three potencies, 20, 40 and 80 mg Telmisartan tablets. The tablet compositions are presented in Table 4.
Table 4: Telmisartan formulations comprising 66% of a water insoluble diluent.
1~..~ i .#I E..t1rs . .~ ~ .. r t ~ 1 4 ~ { S ;~v~~ .3 ~ !~'. E{ik= '~ S ~~~
ki ~s ~.;i~ 1 w:~ ~ii: ~
Telmisartan 20 40 80 12.5 Microcrystalline Cellulose (Avicel PH 102) 105.4 210.8 421.6 65.875 Poloxamer 188 4 8 16 2.5 Meglumine 15 30 60 9.375 Povidone (PVP K-30) 2 4 8 1.25 Sodium starch glycolate 12 24 48 7.5 Magnesium Stearate 1.6 3.2 6.4 1.0 Total 160.0 320.0 640.0 100.0 The tablets were prepared by wet granulation through a method analogous to the method used to prepare the tablets of example 1.
Example 4: Dissolution tests with Telmisartan pharmaceutical tablet dosage forms.
Dissolution tests with the Telmisartan pharmaceutical tablet dosage formulations of examples 1 to 3 were performed. In these tests the dissolution of the tablets of examples 1 to 3 was compared with the dissolution of the reference tablet formulation, a Micardis tablet. These in vitro dissolution tests were conducted using an Apparatus II (Paddle Method) as described in the United State Pharmacopeia XXI/National Formulary XVI. The comparative dissolution tests were conducted under the following conditions. Micardis tablets and Telmisartan tablets of examples 1, 2, and 3 were dissolved in a USP type II apparatus at a paddle speed of 75 rpm, at a temperature of 37 C, in 900ml of a buffer at pH 7.5. The results of these dissolution tests are presented in Table 5.
Table 5: Comparative dissolution.
.
F " i a F k F ~ ~
F~~fJ, 51~~If ~h-kt ] ~ r'~~ =~~f#s~{~~j}{ i~+r~~lf~ Ji ~ } 1 ~ 3~ .. e Based upon these dissolution studies, the results appearing in Table 5 above, it can be concluded that the pharmaceutical tablet formulations of the present invention and the reference Micardis tablet all dissolve at least 80% of the telmisartan contained therein well within the desired 45 minutes. In fact, all dissolve at least 80% of the telmisartan contained in the formulation within 30 minutes, and some formulations even achieve that at least 80% of the telmisartan from the pharmaceutical composition is dissolved in such aqueous solution within 20 minutes. The results further demonstrate that the pharmaceutical tablet formulations of the invention have a similar dissolution profile compared to the 'reference formulation.
Claims (49)
1. A pharmaceutical composition comprising:
a) a telmisartan compound, in admixture with b) a surfactant, c) a basic agent, and d) at least one diluent selected from water soluble and water insoluble diluents, wherein the amount of water soluble diluents in the pharmaceutical composition is less than 25% by weight of the pharmaceutical composition.
a) a telmisartan compound, in admixture with b) a surfactant, c) a basic agent, and d) at least one diluent selected from water soluble and water insoluble diluents, wherein the amount of water soluble diluents in the pharmaceutical composition is less than 25% by weight of the pharmaceutical composition.
2. The pharmaceutical composition according to claim 1, wherein the telmisaran compound comprises an amount from about 12.5% to about 15% of the total weight of the composition.
3. The pharmaceutical composition according to claim 1, wherein at least one diluent is a water insoluble diluent.
4. The pharmaceutical composition according to claim 3, wherein the water insoluble diluent is microcrystalline cellulose.
5. The pharmaceutical composition according to claim 3, wherein the at least one water insoluble diluent comprises an amount from about 40% to about 70% of the total weight of the composition.
6. The pharmaceutical composition according to claim 1, wherein the surfactant is selected from the group consisting of poloxamers, polyethylene glycols, polysorbates, sodium lauryl sulfate, polyethoxylated castor oil, and a hydroxylated castor oil.
7. The pharmaceutical composition according to claim 6, wherein the surfactant is Poloxamer 188.
8. The pharmaceutical composition according to claim 1, wherein the surfactant is in an amount from about 2.0% to about 3.5% of the total weight of the composition.
9. The pharmaceutical composition according to claim 1, wherein the basic agent is selected from the group consisting of alkaline hydroxides, alkaline carbonates, alkaline phosphates, basic amino acids, and Meglumine.
10. The pharmaceutical composition according to claim 9, wherein the basic agent is Meglumine.
11. The pharmaceutical composition according to claim 1, wherein the basic agent is in an amount from about 9% to about 12% of the total weight of the composition.
12. The pharmaceutical composition according to claim 1, wherein the composition further comprises from about 1.0% to about 1.5% of a binder.
13. The pharmaceutical composition according to claim 12, wherein the binder is Povidone.
14. The pharmaceutical composition according to claim 1, wherein the composition further comprises from about 7.5% to about 10% of a disintegrant.
15. The pharmaceutical composition according to claim 14, wherein the disintegrant is sodium starch glycolate.
16. The pharmaceutical composition according to claim 1, wherein the composition further comprises from about 0% to about 17% of a water soluble filler.
17. The pharmaceutical composition according to claim 16, wherein the water soluble filler is sorbitol.
18. The pharmaceutical composition according to claim 1, wherein the composition further comprises from about 0.5% to about 1.0% of a lubricant.
19. The pharmaceutical composition according to claim 18, wherein the lubricant is magnesium stearate.
20. The pharmaceutical composition according to claim 1, wherein at least 80%
of telmisartan dissolves from the composition in a neutral aqueous environment within a period of 45 minutes.
of telmisartan dissolves from the composition in a neutral aqueous environment within a period of 45 minutes.
21. The pharmaceutical composition according to claim 20, wherein the period is 30 minutes.
22. The pharmaceutical composition according to claim 20, wherein the period is 20 minutes.
23. The pharmaceutical composition according to claim 1 in a pharmaceutical dosage form.
24. The pharmaceutical composition according to claim 23, wherein the dosage form is a tablet.
25. The pharmaceutical composition according to claim 24, wherein the tablet comprises an amount of a telmisartan compound selected from 20mg, 40mg, and 80mg.
26. The pharmaceutical composition according to claim 25, wherein the tablet dosage form comprises 20mg of a telmisartan compound.
27. The pharmaceutical composition according to claim 26, wherein the total weight of the tablet dosage form is from about 130mg to about 160mg.
28. A method of preparing a pharmaceutical composition comprising the following steps of mixing a disintegrant and one or more diluents in a high shear mixer to form a homogeneous mixture; preparing a granulation suspension of purified water, alcohol, a basic agent, a surfactant, and telmisartan; combining the homogeneous mixture and the granulation suspension to form a combined mixture; preparing a granulation solution of water and a binder; adding the granulation solution to the combined mixture to form a granulate; drying the formed granules;
sizing the dried granules; mixing the dried granulate with a filler and a disintegrant; and adding a lubricant to form a final mixture, wherein the prepared pharmaceutical composition comprises less than 25% by weight of water soluble diluents.
sizing the dried granules; mixing the dried granulate with a filler and a disintegrant; and adding a lubricant to form a final mixture, wherein the prepared pharmaceutical composition comprises less than 25% by weight of water soluble diluents.
29. The method according to claim 28, further comprising compressing the final mixture into tablets.
30. The method according to claim 28, wherein at least one diluent is water insoluble.
31. The method according to claim 30, wherein the water insoluble diluent is microcrystalline cellulose.
32. The method according to claim 30, wherein the total amount of water insoluble diluents is from about 40% to about 70%.
33. The method according to claim 28, wherein the disintegrant is sodium starch glycolate.
34. The method according to claim 28, wherein the amount of disintegrant used results in a pharmaceutical composition comprising about 7.5% to about 10% of a disintegrant.
35. The method according to claim 28, wherein the basic agent is Meglumine.
36. The method according to claim 28, wherein the amount of a basic agent used results in a pharmaceutical composition comprising about 9% to about 12% of a basic agent.
37. The method according to claim 28, wherein the surfactant is Poloxamer 188.
38. The method according to claim 28, wherein the amount of surfactant used results in a pharmaceutical composition comprising about 2.0% to about 3.5% of a surfactant.
39. The method according to claim 28, wherein the binder is Povidone.
40. The method according to claim 28, wherein the amount of binder used results in a pharmaceutical composition comprising about 1.0% to about 1.5% of a binder.
41. The method according to claim 28, wherein the filler is sorbitol.
42. The method according to claim 28, wherein the amount of water soluble filler used results in a pharmaceutical composition comprising about 0% to about 17% of a water soluble filler.
43. The method according to claim 28, wherein the lubricant is magnesium stearate.
44. The method according to claim 28, wherein the amount of lubricant is from about 0.5%
to about 1.0%.
to about 1.0%.
45. The method according to claim 28, wherein the amount of telmisartan used results in a pharmaceutical composition comprising about 12.5% to about 15.5% of telmisartan.
46. A method of treating a patient suffering from hypertension comprising administering an effective amount of a telmisartan compound in a pharmaceutical composition comprising about 12.5% to about 15.5% of the telmisartan compound; about 2.0 to about 3.5% of a surfactant;
about 9% to about 12% of a basic agent; and at least one diluent, wherein the composition comprises less than 25% of water soluble diluents.
about 9% to about 12% of a basic agent; and at least one diluent, wherein the composition comprises less than 25% of water soluble diluents.
47. The method according to claim 46, wherein the pharmaceutical composition comprises at least one water insoluble diluent.
48. The method according to claim 47, wherein the total amount of water insoluble diluents is from about 40% to about 70%.
49. The method according to claim 47, wherein the insoluble diluent is microcrystalline cellulose.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2005/042700 WO2007061415A1 (en) | 2005-11-22 | 2005-11-22 | Pharmaceutical compositions of telmisartan |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2623018A1 true CA2623018A1 (en) | 2007-05-31 |
Family
ID=36645450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002623018A Abandoned CA2623018A1 (en) | 2005-11-22 | 2005-11-22 | Pharmaceutical compositions of telmisartan |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP2009515956A (en) |
CN (1) | CN101312714A (en) |
AU (1) | AU2005338461A1 (en) |
CA (1) | CA2623018A1 (en) |
IL (1) | IL189614A0 (en) |
WO (1) | WO2007061415A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9427402B2 (en) | 2010-09-30 | 2016-08-30 | Shionogi & Co. Ltd. | Preparation for improving solubility of poorly soluble drug |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8637078B2 (en) * | 2005-11-24 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Bilayer tablet comprising telmisartan and diuretic |
WO2009017812A2 (en) * | 2007-08-01 | 2009-02-05 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition of candesartan |
CZ301070B6 (en) * | 2008-07-31 | 2009-10-29 | Zentiva, A. S. | Telmisartan tablets |
CZ301299B6 (en) * | 2008-11-24 | 2010-01-06 | Zentiva, A.S. | Solid pharmaceutical composition with atorvastatin and telmisartan active ingredients |
CN102552161B (en) * | 2010-12-28 | 2016-06-22 | 上海中西制药有限公司 | The preparation method of a kind of pharmaceutical solid preparation and gained pharmaceutical solid preparation |
CN102532033A (en) * | 2012-02-29 | 2012-07-04 | 江西杏林白马药业有限公司 | Telmisartan salifying process |
US20160193276A1 (en) * | 2012-12-21 | 2016-07-07 | Teva Pharmaceutical Industries, Ltd. | Transmucosal delivery of glatiramer acetate |
JP6379044B2 (en) * | 2013-01-31 | 2018-08-22 | 沢井製薬株式会社 | Multi-layer tablets containing telmisartan and hydrochlorothiazide |
JP6218664B2 (en) * | 2013-04-04 | 2017-10-25 | 沢井製薬株式会社 | Telmisartan-containing tablets |
CN104688696B (en) * | 2013-12-04 | 2017-12-19 | 长春海悦药业股份有限公司 | A kind of pharmaceutical composition containing candesartan Cilexetil |
EP2979691A1 (en) * | 2014-07-30 | 2016-02-03 | Boehringer Ingelheim International GmbH | Oral disintegrating tablet |
JP5871294B1 (en) * | 2015-02-27 | 2016-03-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Immediate release oral tablets |
MX2018013070A (en) | 2017-12-29 | 2019-10-15 | Gruenenthal Gmbh | Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain. |
CN110934848B (en) * | 2019-12-20 | 2022-02-15 | 江西杏林白马药业股份有限公司 | Telmisartan capsule and preparation method thereof |
CN115245497A (en) * | 2021-04-26 | 2022-10-28 | 武汉伯睿科医药科技有限公司 | Telmisartan capsule and preparation process thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2260833B1 (en) * | 2002-01-16 | 2012-11-21 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bilayer pharmaceutical tablet comprising telmisartan and a diuretic |
DE10244681A1 (en) * | 2002-09-24 | 2004-04-08 | Boehringer Ingelheim International Gmbh | New solid telmisartan-containing pharmaceutical formulations and their preparation |
-
2005
- 2005-11-22 CA CA002623018A patent/CA2623018A1/en not_active Abandoned
- 2005-11-22 JP JP2008541140A patent/JP2009515956A/en active Pending
- 2005-11-22 CN CNA2005800521169A patent/CN101312714A/en active Pending
- 2005-11-22 AU AU2005338461A patent/AU2005338461A1/en not_active Abandoned
- 2005-11-22 WO PCT/US2005/042700 patent/WO2007061415A1/en active Application Filing
-
2008
- 2008-02-19 IL IL189614A patent/IL189614A0/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9427402B2 (en) | 2010-09-30 | 2016-08-30 | Shionogi & Co. Ltd. | Preparation for improving solubility of poorly soluble drug |
Also Published As
Publication number | Publication date |
---|---|
IL189614A0 (en) | 2008-06-05 |
JP2009515956A (en) | 2009-04-16 |
WO2007061415A1 (en) | 2007-05-31 |
AU2005338461A1 (en) | 2007-05-31 |
CN101312714A (en) | 2008-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2623018A1 (en) | Pharmaceutical compositions of telmisartan | |
JP4880591B2 (en) | Pharmaceutical composition comprising irbesartan | |
US6517871B1 (en) | Bioenhanced formulations comprising eprosartan in oral solid dosage form | |
TWI428333B (en) | Pharmaceutical compositions | |
JP6875407B2 (en) | A pharmaceutical composition containing a JAK kinase inhibitor or a pharmaceutically acceptable salt thereof. | |
CA2644179C (en) | Novel pharmaceutical composition comprising a disintegration matrix | |
BRPI0716436B1 (en) | controlled release system and method for manufacturing it | |
KR20040101550A (en) | High drug load tablet | |
KR20130091319A (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate | |
CA2801020A1 (en) | A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide | |
US20070116759A1 (en) | Pharmaceutical compositions of telmisartan | |
US10016374B2 (en) | Disintegrant free composition of Cinacalcet | |
US11576917B2 (en) | Pharmaceutical compositions comprising Ibrutinib | |
WO2007049291A1 (en) | Novel solid dosage forms of valsartan and rochlorothiazide | |
US20090030057A1 (en) | Pharmaceutical composition of telmisartan | |
EP2638898A1 (en) | Metformin and Pioglitazone Formulation with Different Release Profiles | |
WO2009017812A2 (en) | Pharmaceutical composition of candesartan | |
US20150224086A1 (en) | Pharmaceutical Formulations of Rufinamide | |
WO2022153330A1 (en) | Pharmaceutical compositions comprising acalabrutinib | |
JP2021528381A (en) | A preparation containing a dopamine-β-hydroxylase inhibitor and a method for preparing the preparation. | |
JP7511596B2 (en) | Rivaroxaban-containing tablets | |
WO2013098578A1 (en) | Immediate release pharmaceutical composition of valsartan hydrochlorothiazide | |
JP2013067574A (en) | Stabilized pharmaceutical composition | |
KR20160112732A (en) | Pharmaceutical compositions comprising potassium salt of telmisartan and Preparation methods thereof | |
WO2022162687A1 (en) | Pharmaceutical compositions comprising nilotinib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20121001 |